Peregrine Pharma (PPHM) +17.1% premarket after reaching agreement with the FDA on the design of...

|About: Peregrine Pharmaceuticals Inc. (PPHM)|By:, SA News Editor

Peregrine Pharma (PPHM) +17.1% premarket after reaching agreement with the FDA on the design of a Phase III trial of its Cotara treatment for recurrent brain cancer. Cotara is a targeted therapy that delivers a high dose of radiation directly into the brain tumor while sparing radiation exposure to healthy brain tissue.